Early vitrectomy in endophthalmitis. Paul R, Simunovic M, Dawkins R, Bhullar G, Essex R, Chang A, Allen P. In clinical and experimental ophthalmology 2019 Nov 1 (vol. 47, pp. 155-155). 111 river st, hoboken 07030-5774, nj usa: wiley.
Ultra-Widefield Fluorescein Angiography as a Biomarker for Response to Switch in Therapy in Persistent DME. Bahrami B, Hong T, Peto T, Chang A. Ophthalmic Surgery, Lasers and Imaging Retina. 2019 Dec 27;50(12):771-8.
Aflibercept for persistent diabetic macular oedema: 48 week outcomes. Bahrami B, Hong T, Schlub T, Chang A. Retina. 1 Jan 2019.
Pharmacotherapy of vitreomacular traction. Wan R, Hong T, Tariq Y, Chang A. Curr Pharm Des 2019.
Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusions: A Systematic Review and Meta-Analysis. Spooner K, Hong T, Fraser-Bell S, Chang A. Asia Pac J Ophthalmol (Phila). 2019 May-Jun;8(3):236-246.
Post‐surgical versus post‐intravitreal injection endophthalmitis: changing patterns in causative flora. Ong AP, Angbue Te N, Zagora SL, Symes RJ, Yates W, Chang AA, McCluskey PJ, Simunovic MP. Clinical & experimental ophthalmology. 2019 Jan;47(1):57-62.
Early pars plana vitrectomy for treatment of acute infective endophthalmitis. Ho IV, Fernandez-Sanz G, Levasseur S, Ting E, Liew G, Playfair J, Downie J, Gorbatov M, Hunyor AP, Chang AA. The Asia-Pacific Journal of Ophthalmology. 2019 Jan 1;8(1):3-7.
Saffron therapy for the treatment of mild/moderate age-related macular degeneration: a randomised clinical trial. Broadhead GK, Grigg JR, McCluskey P, Hong T, Schlub TE, Chang AA. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2019 Jan 28;257(1):31-40.
A meta‐analysis of patients with treatment‐resistant macular oedema secondary to retinal vein occlusions following switching to aflibercept. Spooner K, Hong T, Bahrami B, Chang A. Acta ophthalmologica. 2019 Feb;97(1):15-23.
Five-year outcomes of retinal vein occlusion treated with vascular endothelial growth factor inhibitors. Spooner K, Fraser-Bell S, Hong T, Chang AA. BMJ open ophthalmology. 2019 Mar 1;4(1):e000249.
2020 Research Publications
Optical-coherence tomography angiography and ultrawide-field angiography findings in eyes with refractory macular edema secondary to retinal vein occlusion switched to aflibercept: A subanalysis from a 48-week prospective study. Spooner K, Fraser-Bell S, Hong T, Chang A. Taiwan J Ophthalmol. 2020
Brolucizumab: an evolution in treatment for neovascular age-related macular degeneration. Ong EL, Spooner K, Hong T, Chang A. Expert Review of Ophthalmology. 2020 Mar 3;15(2):71-81.
To Treat or Not to Treat: Management Options for Symptomatic Vitreous Floaters. Broadhead GK, Hong T, Chang AA. The Asia-Pacific Journal of Ophthalmology. 2020 Mar 1;9(2):96-103.
Effects of Switching to Aflibercept in Treatment Resistant Macular Edema Secondary to Retinal Vein Occlusion. Spooner K, Fraser-Bell S, Hong T, Chang A. Asia-Pacific Journal of Ophthalmology: January-February 2020 – Volume 9 – Issue 1 – p 48-53
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. Kunimoto D, Yoon YH, Wykoff CC, Chang A, Khurana RN, Maturi RK, Agostini H, Souied E, Chow DR, Lotery AJ, Ohji M. Ophthalmology. 2020 Apr 9.
Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with VEGF Inhibitors Using a Treat-and-Extend or a Pro-Re-Nata Regimen. Four Year Results of the MANEX Study. Spooner KL, Fraser-Bell S, Cozzi M, Staurenghi G, Invernizzi A, Monteduro D, Munk MR, Hong T, Chang AA. Ophthalmology. 2020 Jun 13.
Does functional assessment predict everyday visual functioning? Visual function testing and quality of life in mild/moderate age-related macular degeneration. Broadhead GK, Hong T, Grigg JR, McCluskey P, Schlub TE, Spooner K, Chang AA. International Ophthalmology. 2020 Jul 14:1-9.
Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long‐term treatment with bevacizumab or ranibizumab. Spooner K, Fraser-Bell S, Hong T, Chang A. Clinical & Experimental Ophthalmology. 2020 Jan;48(1):53-60.
Patient-reported outcomes from a phase IV study of aflibercept in patients with refractory retinal vein occlusions. Spooner K, Fraser-Bell S, Hong T, Chang A. Taiwan J Ophthalmol. 2020
Long-term Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: The LATAR Study: Report 1: Ten-Year, Real-World Outcomes. Spooner K, Fraser-Bell S, Hong T, Phan L, Wong JG, Chang A. Ophthalmol Retina. 2021 Jun;5(6):511-518. doi: 10.1016/j.oret.2020.09.019. Epub 2020 Sep 29.
2021 Research Publications
Long-term outcomes of anti-VEGF treatment of retinal vein occlusion. Spooner KL, Fraser-Bell S, Hong T, Wong JG, Chang AA. Eye (Lond). 2021 Jun 11.
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Ogura Y, Jaffe GJ, Cheung CM, Kokame GT, Iida T, Takahashi K, Lee WK, Chang AA, Monés J, D’Souza D, Weissgerber G. British Journal of Ophthalmology. 2021 Jul 21.
Anti-inflammatory and neuroprotective properties of the corticosteroid fludrocortisone in retinal degeneration. Racic T, Chang A, Fernando N, Brandli A, Natoli R, Penfold P, Provis JM, Rutar M. Exp Eye Res. 2021 Sep 9:108765. doi: 10.1016/j.exer.2021.108765. Epub ahead of print. PMID: 34509498.
Early Residual Fluid-free Status and Long-term BCVA outcomes: A Treatment Agnostic, Post-hoc Analysis of Pooled HAWK and HARRIER Data. Jhaveri, C., Wykoff, C.C., Khanani, A.M., Eandi, C.M., Chang, A., Guruprasad, B., Gedif, K.A. and Singer, M., 2021. American Journal of Ophthalmology.
Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: Consensus and recommendations from the Asia-Pacific Vitreo-Retina Society. Chaikitmongkol V, Sagong M, Lai TYY, Tan G.S, Fariza N, Ohji M, Mitchell P, Yang CH, Raumviboonsik P, Wong I, Sakamoto T, Rajendran A, Chen Y, Wong TY, Cheung CMG, Chang A, Koh A. APJO 2021 In press
Comparison between two multimodal imaging platforms: Nidek Mirante and Heidelberg Spectralis. Spooner K, Phan L, Cozzi M, Hong T, Staurenghi G, Chu E, Chang AA. Graefes Arch Clin Exp Ophthalmol. 2021 Jan 6. doi: 10.1007/s00417-020-05050-7. Epub ahead of print. PMID: 33409677.
Diet and risk of visual impairment: a review of dietary factors and risk of common causes of visual impairment. Broadhead GK, Hong T, Bahrami B, Flood V, Liew G, Chang AA. Nutr Rev. 2021 May 12;79(6):636-650.
Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions. Bowditch E, Chu E, Hong T, Chang AA. Expert Review of Ophthalmology. 2021 May 26.
2022 Research Publications
Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Ogura Y, Jaffe GJ, Cheung CM, Kokame GT, Iida T, Takahashi K, Lee WK, Chang AA, Monés J, D’Souza D, Weissgerber G. British Journal of Ophthalmology. 2022 Jul 1;106(7):994-9.
Early residual fluid-free status and long-term BCVA outcomes: a treatment agnostic, post hoc analysis of pooled HAWK and HARRIER data. Jhaveri C, Wykoff CC, Khanani AM, Eandi CM, Chang A, Guruprasad B, Gedif KA, Singer M. American Journal of Ophthalmology. 2022 Apr 1;236:12-9.
Phase 1B study of the safety and tolerability of the mineralocorticoid fludrocortisone acetate in patients with geographical atrophy. Hong T, Chang A, Maddess T, Provis J, Penfold P. BMJ Open Ophthalmology 2022;0:e001032. doi:10.1136/bmjophth-2022-001032
Transketolase in human Müller cells is critical to resist light stress through the pentose phosphate and NRF2 pathways, Chen Y, Zhang T, Zeng S, Xu R, Jin K, Coorey NJ, Wang Y, Wang K, Lee S, Yam M, Zhu M, Chang A, Fan X, Zhang M, Du J, Gillies MC, Zhu L. Redox Biology, June 2022, 102379, ISSN 2213-2317,
Optical Coherence Tomography Classification Systems for Diabetic Macular Edema and Their Associations With Visual Outcome and Treatment Responses – An Updated Review Hui V ,Szeto S.K.H., Tang F, Yang D, Chen H, Lai T, Rong A, Zhang S, Zhao P, Ruamviboonsuk P, Lai CC, Chang A, Das D, Ohji M, Huang SS, Sivaprasad S, Wong TY, Lam DSC, Cheung CY. Asia-Pacific Journal of Ophthalmology: June 2022 – Volume 11 – Issue 3 – p 247-25
Visualisation of peripheral retinal degenerations and anomalies with ocular imaging. Cheung R, Ly A, Katalinic P, Coroneo MT, Chang A, Kalloniatis M, Madigan MC, Nivison-Smith L. Seminars in Ophthalmology. 2022 Mar 7. DOI: 10.1080/08820538.2022.2039222
YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials Of Faricimab For Diabetic Macular Edema: Study Design And Rationale. Eter N, Singh RP, Abreu F, Asik K, Basu K, Baumal C, Chang A, Csaky KG, Haskova Z, Lin H, Ruiz C Q, Ruamviboonsuk P, Silverman D, Wykoff CC, Willis JR. Ophthalmology Science. 2022 Mar;2(1):100111.
2023 Research Publications
Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER. Sadda S, Sarraf D, Khanani AM, Tadayoni R, Chang AA, Saffar I, Gedif K, Wong DT. British Journal of Ophthalmology. 2023
Retina Update: Entering an Era of Personalized Medicine in Ophthalmology. Chang A, Mieler WF, Ohno-Matsui K, Lai CC. The Asia-Pacific Journal of Ophthalmology. 2023 Mar 1;12(2):111-2.
Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen. Cozzi M, Monteduro D, Esposito RA, Spooner KL, Fraser-Bell S, Staurenghi G, Romano F, Airaldi M, Chang AA, Invernizzi A. Eye. 2023 Jul 1:1-7.
Novel Drug Delivery Methods and Approaches for the Treatment of Retinal Diseases. Ham Y, Mehta H, Kang-Mieler J, Mieler WF, Chang A. The Asia-Pacific Journal of Ophthalmology. 2023 Jul 1;12(4):402-13.
Microperimetry in retinal diseases. Horie S, Giulia C, Esmaeilkhanian H, Sadda SR, Cheung CM, Ham Y, Chang A, Takahashi T, Ohno-Matsui K. The Asia-Pacific Journal of Ophthalmology. 2023 Mar 1;12(2):211-27.
Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors‒the AUSSIEDEX study. Mitchell P, Arnold J, Fraser-Bell S, Kang HK, Chang A, Tainton J, Simon S. BMJ Open Ophthalmology, 2023:107:72-78.
Retinotomies and retinectomies: A review of indications, techniques, results, and complications. Ramamurthy SR, Dave VP, Chou HD, Ozdek S, Parolini B, Dhawahir-Scala F, Wu WC, de Ribot FM, Chang A, Ruamviboonsuk P, Pathengay A. Survey of Ophthalmology. 2023 Jul 3.
KESTREL and KITE Phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, Agostini HT, Chang A, Laude A, Wachtlin J, Kovacic L. American journal of ophthalmology. 2023 Jul 15.
Diabetic Macular Oedema Guidelines: An Australian Perspective. Yuen YS, Gilhotra JS, Dalton M, Aujla JS, Mehta H, Wickremasinghe S, Uppal G, Arnold J, Chen F, Chang A, Fraser-Bell S. Journal of Ophthalmology. 2023 Feb 14;2023.
2024 Research Publications
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases. Chaudhary V, Mar F, Amador MJ, Chang A, Gibson K, Joussen AM, Kim JE, Lee J, Margaron P, Saffar I, Wong D. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2024 Dec 21:1-9.
Subluxated Intraocular Lenses Stabilisation Using A Novel Microvascular Clamp Technique To Facilitate Scleral Suturing. Coroneo MT, Chang A. American Journal of Ophthalmology. 2024 Dec 18.
Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial. Nielsen JS, Chang A, Holekamp NM, Cavichini-Cordeiro M, Lin SL, Heinrich D, Maass KF, Menezes A, Singh N, Pieramici DJ. Ophthalmology Retina. 2024 Dec 1;8(12):1127-39.
What is Occluding Our Understanding of Retinal Vein Occlusion?. Dinah C, Chang A, Lee J, Li WW, Singh R, Wu L, Wong D, Saffar I. Ophthalmology and Therapy. 2024 Oct 10:1-0.
Injections in the back of the eye: The why, the what and when to worry. Broadhead GK, Hong T, Chang AA. Australian Journal of General Practice. 2024 Jul 1;53(7):476-9.
International Classification System for Ocular Complications of Anti-Vascular Endothelial Growth Factor Agents in Clinical Trials. Popovic MM, Balas M, Sadda SR, Sarraf D, Huang R, Bakri SJ, Berrocal A, Chang A, Cheung CM, Garg S, Hillier RJ. Ophthalmology. 2024 Jun 13.
Saffron therapy for the ongoing treatment of age-related macular degeneration. Broadhead GK, Grigg J, McCluskey PJ, Hong T, Schlub TE, Chu E, Chang AA. BMJ Open Ophthalmology. 2024 Mar 1;9(1):e001399.
Case Report: Macula Structural and Functional Assessment in Nab-Paclitaxel–Related Cystoid Macular Edema. Kwok L, Mahmood A, Kumar S, Chang A. Ophthalmic Surgery, Lasers and Imaging Retina. 2024 Mar 1:1-4.
KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema. Wykoff CC, Garweg JG, Regillo C, Souied E, Wolf S, Dhoot DS, Agostini HT, Chang A, Laude A, Wachtlin J, Kovacic L. American journal of ophthalmology. 2024 Apr 1;260:70-83.
Infographic: study design of the BALATON and COMINO phase 3 randomised trials of faricimab in patients with retinal vein occlusion.Chang A, Kotecha A, Kermani F, Saffar I. Eye. 2024 Feb 23:1-2.
TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI. Ophthalmology. 2024 Feb 19.
Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen. Cozzi M, Monteduro D, Esposito RA, Spooner KL, Fraser-Bell S, Staurenghi G, Romano F, Airaldi M, Chang AA, Invernizzi A. Eye. 2024 Jan;38(1):161-7.
Pigment epithelial detachment thickness and variability impacts visual outcomes in patients with neovascular age-related macular degeneration. Sarraf D, Khanani AM, Sadda SR, Chang A, Wong DT, Kempf AS, Saffar I, Tang S, Tadayoni R. Retina. 2024 Jan 44:10-19.
2025 Research Publications
Vacuum evaporation in the vitreous cavity. Jessup A, Chang A. Asia-Pacific Journal of Ophthalmology. 2025 Apr 27:100201.
Dysregulated Proline Metabolism Contributes to Subretinal Fibrosis in Neovascular AMD: Therapeutic Potential of Prolyl-4-Hydroxylase Inhibition. Zeng Y, Zhang T, Cornish E, Lee SR, Yam M, Eminhizer M, Zeng J, Zhang J, Zeng S, Wei X, Yang J, Zhu M, Chang A, Zhang M, Du J, Zhu L, Gillies M. bioRxiv. 2025:2025-04.
Consensus and guidelines on diagnosis and management of polypoidal choroidal vasculopathy (PCV) from the Asia-Pacific Vitreo-retina Society (APVRS). Ruamviboonsuk P, Ng DS, Chaikitmongkol V, Chang A, Chen SJ, Chen Y, Cheung CM, Gomi F, Guymer R, Kim JE, Koh A. Asia-Pacific Journal of Ophthalmology. 2025 Jan 1;14(1):100144.
Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER. Khanani AM, Sadda SR, Sarraf D, Tadayoni R, Wong DT, Kempf AS, Saffar I, Gedif K, Chang A. Ophthalmology Retina. 2025 Jan 1;9(1):13-21.
The CUREOS Clinical Research Network provides research trials, site management and medical writing.
